Skip to content

Effect of an Interdisciplinary Shared Decision-Making Intervention on Decisional Conflict in Advanced Cancer Patients Receiving Third-Line Therapy

Decisional Conflict in Patients With Advanced Cancer in a Shared Decision-Making Model: A Randomized Clinical Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07164365
Acronym
SharedDecision
Enrollment
62
Registered
2025-09-10
Start date
2025-08-10
Completion date
2026-04-30
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decisional Conflict, Advanced/Metastatic Solid Tumors, Shared Decision-making

Keywords

Cancer, advanced disease, decisional conflict, shared decision making, interdisciplinary intervention, oncology, palliative care

Brief summary

The study aims to evaluate whether an interdisciplinary intervention based on a shared decision-making model can reduce decisional conflict in patients with metastatic solid tumors (lung, breast, colorectal, prostate, or ovarian cancer) who are indicated for third-line systemic treatment. Participants are randomized to receive either standard oncology consultation or an additional interdisciplinary consultation involving oncology, palliative care, and psychology. The intervention emphasizes providing information and support for treatment decisions.

Detailed description

* Problem Statement: In Colombia, advanced cancer is common and treatment options become increasingly complex by the third line of therapy, often lacking standardized guidelines. This complexity, along with uncertainty about prognosis and treatment benefits, can lead to significant decisional conflict for patients. * Objective: To determine whether a structured interdisciplinary intervention using shared decision-making reduces decisional conflict compared to standard care. * Population: Adults (≥18 years) with metastatic lung, breast, colon, ovary, or prostate cancer at Hospital San Ignacio, eligible for third-line systemic therapy. * Intervention: The intervention group receives an additional consultation involving a medical oncologist, palliative care physician, and psychologist. The session follows six steps: inviting the patient to participate, describing options, detailing benefits and risks, clarifying patient goals, facilitating decision deliberation, and outlining next steps-all based on the shared decision-making model. * Control Group: Receives standard oncology consultation only. * Randomization: Assignment is done randomly and independently. * Outcomes: * Primary: Decisional conflict measured by the Decisional Conflict Scale. * Secondary: Patient satisfaction, decision regret, perceptions of shared decision-making, symptom burden, and levels of neuroticism, all assessed with validated instruments. * Sample Size: 62 participants (31 per group) are planned, allowing for potential losses. * Follow-up: Patients are assessed immediately after intervention/consultation and again at three months. * Analysis: Data will be analyzed by intention-to-treat, using quantitative scales, and adjusting for confounding factors. Subgroup analyses by demographic and clinical characteristics are planned. Overall, the study is designed to inform best practices on supporting advanced cancer patients in complex treatment decisions, exploring the effects of an interdisciplinary, patient-centered intervention on decisional conflict and related outcomes.

Interventions

BEHAVIORALInterdisciplinary Shared Decision-Making Consultation

One additional face-to-face consultation with a team (oncologist, palliative care, psychologist), following a six-step shared decision-making process.

Sponsors

Hospital Universitario San Ignacio
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized clinical trial; parallel two-arm design (intervention and control)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Diagnosed with metastatic lung, breast, colon, ovary, or prostate cancer * Have completed two prior lines of systemic therapy * Indication for third-line systemic therapy (chemotherapy, immunotherapy, or hormone therapy) * Under follow-up at Hospital San Ignacio * Capacity to provide informed consent *

Design outcomes

Primary

MeasureTime frameDescription
Decisional Conflict ScoreImmediately post-interventionMeasured using the Decisional Conflict Scale (16 items); score ≥25 defines clinically significant conflict

Secondary

MeasureTime frameDescription
Patient satisfactionImmediately post-intervention and at 3 months follow-upMeasure of the importance of patient satisfaction as a key quality indicator and highlights the use of the Likert scale as an effective tool for measuring perceptions of healthcare quality. The objective is to evaluate patient satisfaction by using the Likert scale, where scores of 7 denote satisfaction, and scores different from 7 indicate dissatisfaction.
Decision regretat 3 months after de interventionUse of the Decision Regret Scale (EAD) to measure patients' regret after making healthcare decisions. The objective is to assess the level of decision regret, with higher scores indicating greater regret, to better understand patients' emotional responses and improve decision-making processes.
Perspective on shared decision-makingImmediately post-interventionThis is a short, patient-centered questionnaire to assess the shared decision-making process in clinical settings. It is psychometrically robust, easy to use, and provides both an overall score and item-level insights, making it valuable for evaluating interventions and improving patient-physician collaboration in healthcare decisions.
Symptom burden1 day after intervention and 3 months post interventionWe are going to measure this using the Edmonton Symptom Assessment Scale (ESAS) is a brief, patient-completed tool designed to assess the severity of common symptoms in palliative care, especially among cancer patients. It uses 10 visual numeric scales to evaluate both physical and psychological symptoms, is validated in multiple languages, and is widely used in clinical and research settings for ongoing symptom monitoring.
Neuroticism traitImmediately post-interventionWe are going to measure this using the MMPI-2, which is a comprehensive psychological assessment tool designed to evaluate a wide range of personality traits and psychopathological conditions. It is widely used in clinical and research settings, and for this study, only the neuroticism dimension will be assessed using a subset of 33 items. The results are interpreted using standardized T scores, with higher scores indicating greater psychological distress or maladaptive traits.

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026